Source record
The FDA’s current drug concerns
The FDA distinguishes compounded weight-loss drugs from approved products, as of September 26, 2026.
Read the sourceUnderstand the drug
Is the named drug approved?
Ask about the exact product, its form and the proposed use. A broad claim about peptides leaves too much out.
Which names have approved products?
FDA-approved products include semaglutide under the names Ozempic and Wegovy, plus tirzepatide under Mounjaro and Zepbound, as of September 26, 2026.
Ozempic and Wegovy each have both injection and tablet products in the approval record at that date.
Ask the clinician to name the form and explain the proposed use. A brand name alone is not the full answer.
Which names lack a U.S. approval?
As of September 26, 2026, FDA application records show no approved U.S. drug for BPC-157, ipamorelin or retatrutide.
The FDA states that making retatrutide and cagrilintide as custom medicines is not allowed under federal law at that date.
Ask to see the FDA’s approval for the exact medicine. A popular name or a mention in a study does not answer whether it is approved.
A generic is different from a custom medicine.
Neither semaglutide nor tirzepatide has an FDA-approved generic that may be sold in the United States, as of September 26, 2026.
Generic liraglutide products do exist, including versions approved for weight management.
A pharmacy-made medicine, called compounded, is not an FDA-approved generic.
Ask which word describes the actual product in the prescription.
The record behind the answer.
Source record
FDA approval data
Ask the health professional to find the exact medicine in Drugs@FDA and show you its approval. Check that the medicine and form match the offer.
Read the source